TRPV1 inhibition does not prevent cold dry air-elicited symptoms in non-allergic rhinitis

Abstract

SB-705498 12 mg for 14 days did not alleviate the CDA-induced symptoms of NAR. Despite engagement of the TRPV1 receptor, there was no translation to clinical efficacy, suggesting redundancy in symptom pathways.